Full Breakdown
Advances in Treatment for Platinum-Resistant Ovarian Cancer
4/11/2026, 3:11:38 AM
Promising Clinical Trials for New Therapies
Recent clinical trials have highlighted significant advancements in the treatment of platinum-resistant ovarian cancer, a challenging form of the disease that typically offers limited survival options. Two key studies have emerged, focusing on the efficacy of relacorilant and pembrolizumab, both of which have shown potential to extend patient survival.
The first study, published in *The Lancet*, involved 381 patients with platinum-resistant ovarian cancer. Participants received either standard treatment or relacorilant, a drug originally developed for Cushing’s syndrome. Results indicated a 35% reduction in the risk of death for those treated with relacorilant, with an average survival extension of four months compared to the control group. This finding positions relacorilant as a potential new standard treatment option, pending further testing.
In a separate phase 3 trial, pembrolizumab, an anti-PD-1 immunotherapy, was evaluated alongside chemotherapy. This study enrolled 643 patients across 25 countries and demonstrated that the combination of pembrolizumab with weekly paclitaxel significantly improved overall survival. Patients receiving this regimen had a median overall survival of 18.2 months compared to 14.0 months for those on placebo. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved this treatment regimen, particularly for patients whose tumors express the PD-L1 biomarker.
Key Figures in the Research
Dr. Emese Zsiros, Chair of Gynecologic Oncology at Roswell Park Comprehensive Cancer Center, co-led the pembrolizumab study. She emphasized the importance of these findings, stating, “Progress has been difficult to achieve for patients with ovarian cancer that does not respond to platinum-based chemotherapy.” The studies underscore a collaborative international effort to improve treatment outcomes for this difficult-to-treat cancer.
Criticism & Opposition
Despite the promising results, some experts caution that the long-term efficacy and safety of these treatments remain to be fully established. Concerns about potential side effects and the need for further research into the optimal patient populations for these therapies have been raised. Critics argue that while the results are encouraging, they should be interpreted with caution until more extensive data is available.
Conflicting Reports & Gaps
While both relacorilant and pembrolizumab have shown positive results, discrepancies exist regarding the specific patient populations that benefit most from these treatments. The relacorilant study focused on a smaller cohort, while the pembrolizumab trial included a broader range of participants, leading to varying conclusions about the generalizability of the findings.
What's Next
Upcoming presentations, including Dr. Zsiros's findings at the Society of Gynecologic Oncology Annual Meeting, will provide further insights into these trials. Additionally, ongoing studies will continue to explore the efficacy of these treatments, with hopes of establishing new standards of care for patients with platinum-resistant ovarian cancer.
Verbatim Quotes
- “What we’ve learned through this large international effort represents an important step forward in the treatment landscape.” — Dr. Emese Zsiros, Chair of Gynecologic Oncology at Roswell Park Comprehensive Cancer Center.
- “Progress has been difficult to achieve for patients with ovarian cancer that does not respond to platinum-based chemotherapy,” — Dr. Emese Zsiros.
